Literature DB >> 26680058

Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular Carcinoma Awaiting Orthotopic Liver Transplantation.

M I Sánchez-Lorencio1, P Ramirez2, L Saenz3, M V Martínez Sánchez4, V De La Orden5, B Mediero-Valeros5, S Veganzones-De-Castro5, A Baroja-Mazo6, B Revilla Nuin6, M R Gonzalez2, P A Cascales-Campos2, J A Noguera-Velasco1, A Minguela4, E Díaz-Rubio7, J A Pons8, P Parrilla2.   

Abstract

INTRODUCTION: Orthotopic liver transplantation (OLT) is considered one of the few curative treatments available for early stages of hepatocellular carcinoma (HCC). It has been shown that more than 10% of transplanted individuals suffer relapse during the first year after surgery and most of them die because of the tumor. The circulating tumor cells (CTCs) are the main source of recurrences as they disseminate from a primary or metastatic tumor lesion through peripheral blood. We aimed to determine the concentration of CTCs in peripheral blood in these patients by 2 different approaches: the CellSearch and the IsoFlux systems to assess their applicability to this disease monitoring. PATIENTS AND METHODS: A comparative study was conducted in 21 patients with HCC eligible for liver transplantation according to the Milan criteria, whose peripheral blood was processed by the CellSearch and the IsoFlux systems.
RESULTS: CTCs were isolated in 1 of the 21 patients (4.7%) by the CellSearch system and in 19 of the 21 patients (90.5%) by the IsoFlux method. The comparison of both methods using Bland-Altman plot shows that there is not consistency in the determination of CTCs in our patients, finding a proportional bias between them.
CONCLUSION: The results obtained by both CTCs isolation systems are not interchangeable nor transferable. The CellSearch system does not seem to be the ideal approach for studying CTCs in patients with HCC. The IsoFlux system displays greater sensitivity in the identification of CTCs and might become an important tool in patient management.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26680058     DOI: 10.1016/j.transproceed.2015.10.003

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  12 in total

1.  A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.

Authors:  Colin M Court; Shuang Hou; Paul Winograd; Nicholas H Segel; Qingyu Wilda Li; Yazhen Zhu; Saeed Sadeghi; Richard S Finn; Ekambaram Ganapathy; Min Song; Samuel W French; Bita V Naini; Shonan Sho; Fady M Kaldas; Ronald W Busuttil; James S Tomlinson; Hsian-Rong Tseng; Vatche G Agopian
Journal:  Liver Transpl       Date:  2018-07       Impact factor: 5.799

Review 2.  Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer.

Authors:  Margherita Correnti; Chiara Raggi
Journal:  Oncotarget       Date:  2017-01-24

3.  Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer.

Authors:  Daniel Brungs; David Lynch; Alison Ws Luk; Elahe Minaei; Marie Ranson; Morteza Aghmesheh; Kara L Vine; Martin Carolan; Mouhannad Jaber; Paul de Souza; Therese M Becker
Journal:  World J Gastroenterol       Date:  2018-02-21       Impact factor: 5.742

Review 4.  The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy.

Authors:  Arutha Kulasinghe; Hanjie Wu; Chamindie Punyadeera; Majid Ebrahimi Warkiani
Journal:  Micromachines (Basel)       Date:  2018-08-10       Impact factor: 2.891

5.  Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma.

Authors:  Jing-Jing Yu; Wei Xiao; Shui-Lin Dong; Hui-Fang Liang; Zhi-Wei Zhang; Bi-Xiang Zhang; Zhi-Yong Huang; Yi-Fa Chen; Wan-Guang Zhang; Hong-Ping Luo; Qian Chen; Xiao-Ping Chen
Journal:  BMC Cancer       Date:  2018-08-20       Impact factor: 4.430

6.  Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays.

Authors:  Joanna Budna-Tukan; Monika Świerczewska; Martine Mazel; Wojciech A Cieślikowski; Agnieszka Ida; Agnieszka Jankowiak; Andrzej Antczak; Michał Nowicki; Klaus Pantel; David Azria; Maciej Zabel; Catherine Alix-Panabières
Journal:  Cancers (Basel)       Date:  2019-06-10       Impact factor: 6.639

Review 7.  Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.

Authors:  María Lola Espejo-Cruz; Sandra González-Rubio; Javier Zamora-Olaya; Víctor Amado-Torres; Rafael Alejandre; Marina Sánchez-Frías; Rubén Ciria; Manuel De la Mata; Manuel Rodríguez-Perálvarez; Gustavo Ferrín
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

8.  Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation.

Authors:  Víctor Amado; Sandra González-Rubio; Javier Zamora; Rafael Alejandre; María Lola Espejo-Cruz; Clara Linares; Marina Sánchez-Frías; Gema García-Jurado; José Luis Montero; Rubén Ciria; Manuel Rodríguez-Perálvarez; Gustavo Ferrín; Manuel De la Mata
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

9.  Binary-blend fibber-based capture assay of circulating tumor cells for clinical diagnosis of colorectal cancer.

Authors:  Ai-Wei Lee; Fu-Xiang Lin; Po-Li Wei; Guo Jian-Wei; Jem-Kun Chen
Journal:  J Nanobiotechnology       Date:  2018-01-16       Impact factor: 10.435

10.  Magnetic-Based Enrichment of Rare Cells from High Concentrated Blood Samples.

Authors:  Junhao Wu; Katharina Raba; Rosa Guglielmi; Bianca Behrens; Guus Van Dalum; Georg Flügen; Andreas Koch; Suraj Patel; Wolfram T Knoefel; Nikolas H Stoecklein; Rui P L Neves
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.